| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA656: Siponimod for treating secondary progressive multiple sclerosis |
|
Medicine details |
|
| Medicine name | siponimod (Mayzent®) |
| Formulation | 0.25 mg, 1 mg, 2 mg film-coated tablet |
| Reference number | 2305 |
| Indication | Treatment of adult patients with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/12/2019 |
| NICE guidance | TA656: Siponimod for treating secondary progressive multiple sclerosis |
| Commercial arrangement | PAS |